How Precise are Nanomedicines in Overcoming the Blood–Brain Barrier? A Comprehensive Review of the Literature
Priyadarshini Mohapatra,Mohanraj Gopikrishnan,George Priya Doss C,Natarajan Chandrasekaran
DOI: https://doi.org/10.2147/ijn.s442520
IF: 7.033
2024-03-09
International Journal of Nanomedicine
Abstract:Priyadarshini Mohapatra, 1 Mohanraj Gopikrishnan, 2 George Priya Doss C, 2 Natarajan Chandrasekaran 1 1 Centre for Nanobiotechnology, Vellore Institute of Technology, Vellore, TN, 632014, India; 2 Department of Integrative Biology, School of Bioscience and Technology, Vellore Institute of Technology, Vellore, TN, 632014, India Correspondence: Natarajan Chandrasekaran, Centre for Nanobiotechnology, Vellore Institute of Technology, Vellore, TN, 632014, India, Tel +91 416 2202624, Fax +914162243092, Email ; New nanotechnology strategies for enhancing drug delivery in brain disorders have recently received increasing attention from drug designers. The treatment of neurological conditions, including brain tumors, stroke, Parkinson's Disease (PD), and Alzheimer's disease (AD), may be greatly influenced by nanotechnology. Numerous studies on neurodegeneration have demonstrated the effective application of nanomaterials in the treatment of brain illnesses. Nanocarriers (NCs) have made it easier to deliver drugs precisely to where they are needed. Thus, the most effective use of nanomaterials is in the treatment of various brain diseases, as this amplifies the overall impact of medication and emphasizes the significance of nanotherapeutics through gene therapy, enzyme replacement therapy, and blood-barrier mechanisms. Recent advances in nanotechnology have led to the development of multifunctional nanotherapeutic agents, a promising treatment for brain disorders. This novel method reduces the side effects and improves treatment outcomes. This review critically assesses efficient nano-based systems in light of obstacles and outstanding achievements. Nanocarriers that transfer medications across the blood-brain barrier and nano-assisted therapies, including nano-immunotherapy, nano-gene therapy, nano enzyme replacement therapy, scaffolds, and 3D to 6D printing, have been widely explored for the treatment of brain disorders. This study aimed to evaluate existing literature regarding the use of nanotechnology in the development of drug delivery systems that can penetrate the blood-brain barrier (BBB) and deliver therapeutic agents to treat various brain disorders. Keywords: drug delivery, nanomedicine, nano-therapeutics, nanocarriers, blood-brain barrier Graphical The incidence and prevalence of central nervous system (CNS) illnesses are progressively rising, posing serious threats to human life, and increasing socioeconomic expenses associated with providing medicinal treatment. 1 The number of disability-adjusted life-years (DSLYs), a crucial indicator of the burden of neurological diseases, is rising. 2 In India, the incidence of neurological disorders is growing alarmingly—stroke (37.9%), headache disorders (17.5%), epilepsy (11.3%), cerebral palsy (5.7%), and encephalitis (5.3%). 3 The two categories of CNS diseases that affect the brain's neurological functions are acute brain injury and neurodegenerative disorders. The most common brain injuries are stroke, cerebral ischemia, and epilepsy, whereas chronic injuries include Alzheimer's Disease (AD), Parkinson's Disease (PD), and Huntington's disease. 4 Neurological disorders involve the progressive deterioration of neuronal structure and function, often leading to neural death. 5 These disorders affect the central and peripheral nervous systems, including the brain, spinal cord, cranial and peripheral nerves, nerve roots, autonomic nervous system (ANS), neuromuscular junctions, and muscles. These disorders include cerebrovascular diseases, PD, AD, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, brain tumors, stroke, neuroinfections, autism spectrum disorders, and schizophrenia. 6,7 The presence of peripheral and blood–brain barriers (BBB) makes it more challenging to deliver drug molecules to target sites in the CNS. 8 The most delicate and intricate organs in the human brain are shielded by the BBB. It protects brain neurons against destructive and poisonous substances in the blood and disturbs drug penetration into brain tissues. 9 The brain is differentiated from the other parts of the body by strong barriers that prevent the transfer of drug molecules to the CNS. These limitations necessitate the development of new therapeutic approaches to treat brain diseases. Figure 1 introduces innovative nanoparticle (NP)-based brain medication delivery methods. 10 Figure 1 Represents the dynamic landscape of nanomedicine, providing a detailed insight into the multifaceted strategies propelling advances in brain drug delivery and describing the design of novel NP-based techniques and tactics aimed at delivering drugs to the brain. Recently, nanotechnology h -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology